Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The Supreme Court could strike down the constitutionality of the Consumer Financial Protection Bureau, an agency Elizabeth Warren has likened to her child and which Justice...2020 Electionsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
The iShares Nasdaq Biotechnology ETF (IBB) popped more than 2 percent on Wednesday, after a U.S. report on Medicare spending showed the government insurer's growth rate hasn't exceeded a target that could trigger cost cuts.
The ETF ended the day modestly higher.
The reprieve relates to a provision in the Affordable Care Act focused on Medicare spending. If spending growth by the government insurer surpasses a certain threshold, a group called the Independent Payment Advisory Board (IPAB) is tasked with recommending cost reductions. Investors feared this could be triggered for 2016, leading to lower spending on drugs.
"Medicare spending didn't trigger initiation of the Independent Payment Advisory Board to slash costs, a relief for the beleaguered drug industry whose shares have slumped since the start of the year" Art Hogan, of Wunderlich Securities said in an email to CNBC.
Proposals from IPAB could affect biotechnology companies, hospitals and insurers, with some restrictions.
"This is probably one of maybe five or six things health care investors were concerned about. ... My sense is a fairly low probability IPAB gets enacted and is a cost-cutting device," said Mike Bailey, director of research and chair at FBB Capital Partners.
"In my mind there are other concerns investors should focus on first," he said, referring to potential cost cuts by pharmacy management and insurance companies.
After the Medicare news, the iShares Nasdaq Biotechnology ETF (IBB) reversed earlier losses, to hold more than 1 percent higher. Celgene, Regeneron, Gilead were among the biggest positive influences on biotech index on Wednesday. The IBB fell more than 2 percent Tuesday amid concerns of a trigger to creating IPAB.
Analysts at Jefferies say IPAB is still a concern for the sector, and that much more will be needed to maintain the rally. "It will, though, be important to keep IPAB on the radar for 2017, and with reimbursement/election remaining overhangs for the group, we believe increased M&A activity, positive major clinical data, and/or substantial revenue beats would be needed to fuel a more sustainable rally."
Concerns over pricing pressure have contributed to declines for biotech stocks, with the IBB still down about 24 percent this year.
— CNBC's Evelyn Cheng contributed to this report